Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SU
Supernus Pharmaceuticals, Inc.
SUPN
Mkt Cap
$2.20B
Volume
1.33M
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
SU
SUPN
SU
Supernus Pharmaceuticals, Inc.
SUPN
News
·
Why Supernus Pharmaceuticals Stock Topped the Market Today
Mkt Cap
$2.21B
Volume
1.33M
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Insider
Filings
Why Supernus Pharmaceuticals Stock Topped the Market Today
Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.
The Motley Fool · Aug 3, 2026
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating three major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations involve Supernus Pharmaceuticals' sale to Indivior, Integer Holdings' acquisition by KKR, and Bowhead Specialty Holdings' sale to American Family Mutual Insurance. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.
GlobeNewswire Inc. · Aug 3, 2026
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals announced that President and CEO Jack A. Khattar will participate in a fireside chat at the Bank of America 2026 Health Care Conference on May 12, 2026. The company reported strong Q1 2026 financial results with total revenues of $207.7 million, representing a 39% increase year-over-year, with combined revenues from four growth products reaching $149.1 million.
GlobeNewswire Inc. · May 6, 2026
Supernus Pharmaceuticals to Participate in March Investor Conferences
Supernus Pharmaceuticals announced that management will participate in three major healthcare investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference (March 2), Jefferies Biotech on the Beach Summit (March 10), and Barclays 28th Annual Global Healthcare Conference (March 11). Live webcasts will be available for select presentations.
GlobeNewswire Inc. · Feb 23, 2026
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back
Aristotle Capital Boston reduced its holdings in Pharmaceuticals by 503,122 shares in Q3, decreasing its position value by approximately $10.9 million. Despite a 31% stock price increase over the past year, the company remains below its 2018 highs.
The Motley Fool · Dec 16, 2025
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the HSR Act waiting period for its proposed acquisition of Sage Therapeutics, with the tender offer continuing and set to expire on July 30, 2025.
Benzinga · Jul 28, 2025
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will host a conference call on February 25, 2025, to discuss its fourth quarter and full-year 2024 financial results.
GlobeNewswire Inc. · Feb 11, 2025
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, announced that its President and CEO will participate in a fireside chat at the Piper Sandler Healthcare Conference.
GlobeNewswire Inc. · Nov 26, 2024
Attention-Deficit Hyperactivity Disorder Treatment Market is projected to Reach USD 15.4 Billion, Garnering A 3.1% CAGR from 2024 to 2034 | Report Analysis by Transparency Market Research Inc.
The global ADHD treatment market is expected to grow at a CAGR of 3.1% from 2024 to 2034, reaching $15.4 billion by 2034. The growth is driven by increased awareness of ADHD and ongoing research and development efforts.
GlobeNewswire Inc. · Aug 12, 2024
Supernus Pharmaceuticals to Announce Second Quarter 2024 - GlobeNewswire
Supernus Pharmaceuticals, a biopharmaceutical company focused on central nervous system diseases, will announce its Q2 2024 financial results and host a conference call on August 6, 2024.
GlobeNewswire Inc. · Jul 23, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
SU
SUPN
Supernus Pharmaceuticals, Inc.
Buy
Sell
Market
Limit
Soon
SUPN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any SUPN yet.
Related Tickers
Earnings